Фторафур®. Перспективы применения в современной клинической онкологии

1. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8.
2. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537–41.
3. Au JL, Sadee W. The pharmacology of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil). Recent Res Cancer Res 1981; 76: 100–14.
4. Au JL, Wu AT, Friedman MA, Sadee W. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep 1979; 63: 343–50.
5. Anttila MI, Sotaniemi EA, Kairaluoma MI et all. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 1983; 10: 150–3.
6. Komatsu T, Yamazaki H, Shimada N et al. Involvement of Microsomal Cytochrome P450 and Cytosolic Thymidine Phosphorylase in 5-Fluorouracil Formation from Tegafur in Human Liver. Clinical Cancer Research, March 2001; 7: 675–81.
7. Anttila MI, Sotaniemi EA, Kairaluoma et al. Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 1983; 10: 150–3.
8. Блохин Н.Н., Переводчикова Н.И. Химиотерапия опухолевых заболеваний. М.: Медицина, 1984; 82.
9. Апинис Т.А., Мейрена Д.В., Гилев А.П. и др. Экспериментальная и клиническая фармакотерапия. Рига: Зинатне, 1977; Вып. 7: 93–9.
10. Grem JL. 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy. B.A.Chabner, D.L.Longo (eds.). 2nd ed, Philadelphia: Lippincott-Raven Publishers, 1996; 149–211.
11. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983; 1: 107–10.
12. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993; 11: 1879–87.
13. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–44.
14. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.
15. Nogue M, Saigi E, Segui MA. Clinical experience with tegafur and low dose oral leucovorin: a dose-finding study. Oncology 1995; 52: 167–9.
16. Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. Acta Oncol 1987; 26: 433–6.
17. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon, or rectum. Oncology (Basel) 1986; 43: 212–215 Kajanti MJ, Pyrhonen S, Maiche A. Oral tegafur in the treatment of metastatic breast cancer: Phase II study. Eur J Cancer 1993; 29A: 863–6.
18. Palmeri S, Gebbia V, Russo A et al. Oral tegafur in the treatment of gastrointestinal tract cancers: a Phase II study. Br J Cancer 1990; 61: 475–8.
19. Gonzalez-Baron M, Vicente J, Tomas M et al. Phase II trial of cisplatin and tegafur as initial therapy in squamous-cell carcinoma of the head and neck. Am J Clin Oncol 1990; 13 (4): 312–4.
20. Gonzalez-Larriba JL, Garcia Carbonero I, Sastre Valera J et al. Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer. Oncology (Huntingt) 1997; 11 (suppl. 10): 90–7.
21. Calvo FA, Matute R, Garcia-Sabrido JL et al. Neoadjuvant Chemoradiation With Tegafur in Cancer of the Pancreas: Initial Analysis of Clinical Tolerance and Outcome. American Journal of Clinical Oncology. August 2004; 27 (4): 343–9.
22. Ulrich-Pur H, Raderer M, Kornek GV et al. Treatment of Advanced Gastric Cancer with Oral Idarubicin, Leucovorin, and Tegafur. Onkologie 1999; 22: 292–4.
23. Kurihara M, Izumi T, Yoshida S et al. A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991; 82: 613–20.
24. Sasagawa T, Ho N, Endo T et al. Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer. Jpn J Cancer 1994; 21: 1179–85.
25. Jin M, Yang B, Zhang W et al. High-dose mitomycin C-containing regimens in the treatment of advanced gastric cancer. Semin Surg Oncol 1994; 10: 114–6.
26. Malet-Martino M., Martino R. Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review. Oncologist 2002; 7; 288–323.
27. Cirera L, Balil A, Batiste-Alentorn E et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17 (12): 3810–5.
28. Arima S, Ohsato K, Hisatsugu T et al. Multicentre randomized study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 1994; 160: 227–32.
29. Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer. Acta Oncol 1987; 26: 433–6.
30. Bedikian AY, Stroehlein J, Korinek J et al. A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6: 181–6.
31. Losa AF, Cirera L, Mendez M et al. Randomized phase IV trial of oral tegafur and low dose leucovorin versus intravenous 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer (ACC): Final results. ASCO 2004, J Clin Oncol 2004; 23: ab 3547.
32. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 1009a.
33. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of OrzelR (oral Uracil/Tegafur (UFT™) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: 1015a.
34. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetic of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349–58.
35. Malet-Martino M, Martino R. Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review. Oncologist 2002; 7: 288–323.
36. Yoshikawa R, Kusunoki M, Yanagi H et al. New chemotherapeutic strategy for colorectal cancer by "pharmacokinetic modulating chemotherapy (PMC)". Proc Am Soc Clin Oncol 2001; 20: 3085a.
37. Yoshikawa R, Kusunoki M, Yanagi H et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 1029–37.
38. Yamagi H, Kusunoki M, Yoshikawa R et al. Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5-FU infusion and oral UFT after resection of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2001; 20: 556a.
39. Guangchuan XU, Tiehua RONG, Peng LIN et al. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chinese Medical Journal 2000; 113 (7): 617–20.
40. Tashiro H, Nomura Y, Ohsaki A. A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn J Clin Oncol 1994; 24: 212–7.
41. Iglesias L, Moreno JA, Torrija E et al. UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla, Seville, Spain. Oncology (Huntingt) 1997; 11 (suppl. 10): 74–81.
42. Hata Y, Uchino J, Asaishi K et al. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group. Oncology (Huntingt) 1999; 13 (suppl. 3): 91–5.
43. Sugimachi K, Maehara Y, Akazawa K et al. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer. Breast Cancer Res Treat 1999; 56: 113–24.
44. Galmarini CM, Garbovesky C, Galmarini D et al. Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer. Med Oncol 2002; 19 (4): 227–32.

С.Л.Гуторов 

Отделение химиотерапии и комбинированного лечения злокачественных опухолей ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва